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In order to characterize the expression of the viral interleukin-6 (vIL-6) homologue in
various human herpesvirus 8 (HHV-8)–associated diseases, in situ hybridization and immu-
nohistochemistry were applied to formalin-fixed specimens. These assays showed consistent
expression of vIL-6 in primary effusion lymphomas and in a case of human immunodeficiency
virus (HIV)–associated lymphadenopathy with a Castleman’s disease–like appearance. In con-
trast, Kaposi’s sarcoma specimens showed marked differences among specimens. In a con-
secutive series of specimens from the Johns Hopkins archives, vIL-6 expression was dem-
onstrated in one of 13 cases. However, among 7 specimens selected from the AIDS Malignancy
Bank because of their high levels of the T1.1 lytic transcript and virion production, vIL-6
expression was consistently demonstrated in infiltrating mononuclear cells and occasional
spindle-shaped cells. Thus vIL-6 expression in clinical specimens correlates with other mea-
sures of the lytic viral cycle. Both assays generally give congruent results and are consistent
with the possibility that vIL-6 expression plays a role in the pathogenesis of a variety of HHV-
8–associated diseases.
Interleukin-6 (IL-6) has been implicated in the pathogenesis
of a variety of proliferative disorders, including lymphoma,
multiple myeloma, Kaposi’s sarcoma (KS), and Castleman’s
disease [1–3]. The discovery of a homologue of IL-6 in human
herpesvirus 8 (HHV-8) with 24.8% amino acid identity sug-
gested the possibility that this viral cytokine might play a role
in the pathogenesis of HHV-8–associated diseases [4, 5]. Similar
to its human counterpart, viral IL-6 (vIL-6) promotes growth
and proliferation of the mouse plasmacytoma B9 cell line [4].
Previous investigations have demonstrated vIL-6 expression in
a primary effusion lymphoma, in a lymph node of a patient
with KS, and in a case of human immunodeficiency virus
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(HIV)–negative Castleman’s disease, but not in a series of KS
lesions [5, 6]. Here we apply immunohistochemistry comple-
mented by in situ hybridization to detect vIL-6 expression in
a variety of lesions, including primary effusion lymphoma,
HIV-associated lymphadenopathy with Castleman’s disease–
like appearance, and KS.
Materials and Methods
Cell lines and diseased tissue specimens. Formalin-fixed pri-
mary effusion lymphoma specimens were obtained from the pa-
thology archives of Johns Hopkins Hospital, New York Hospital,
and Nashville Veterans Administration Hospital. A hyperplastic
lymph node with Castleman’s disease–like features was obtained
from the Johns Hopkins Hospital. Formalin-fixed, paraffin-em-
bedded archival biopsy specimens of KS tumors were obtained
from Johns Hopkins dermatology archives and the National Can-
cer Institute–funded AIDS Malignancy Bank. GenBank accession
numbers for HHV-8 subtype variants at open-reading frame (ORF)
K1 include the following: AF133038(A1), AF133039(A4),
AF133040(B), and AF133042(C3).
In situ hybridization and immunocytochemistry. In situ hybrid-
ization for vIL-6 was performed, as described elsewhere [7]. The
full-length vIL-6 coding sequence was cloned into the pSK (blues-
cript) vector (Stratagene, La Jolla, CA) between the T7 and T3
RNA polymerase promoters. The T7 RNA polymerase was used
to transcribe the antisense strands. Plasmids were linearized and
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transcribed in vitro by use of digoxigenin-UTP (Boehringer Mann-
heim, Indianapolis, IN) to generate sense and antisense riboprobes.
Slides were deparaffinized in xylene and were rehydrated in de-
creasing concentrations of ethanol. Cells were made permeable with
0.3% Triton X-100 and were digested with proteinase K (20 mg/
mL) in 100 mM Tris-HCl and 50 nM EDTA at pH 8.0 for 7 min
at 377C. The denatured digoxigenin-labeled riboprobes were ap-
plied to slides in a hybridization mix containing 50% formamide,
10% dextran sulfate, 1% polyvinylpyrrolidine, 53 Denhardt’s so-
lution, 0.5% SDS, and 100 mg/mL salmon sperm DNA in 53 sub-
acute sclerosing panencephalitis (SSPE; 0.9 M NaCl, 50 mM
NaH2PO4, and 5 mM EDTA at pH 7.4). Specimens were hybridized
for 16 h at 557C in a sealed humidified chamber. Slides were washed
once each in 23 SSPE with 0.1% SDS and 0.13 SSPE with 0.1%
SDS for 5 min at room temperature and were incubated in RNase
A (Boehringer Mannheim) at 10 mg/mL for 10 min. Hybridization
was detected by use of an antidigoxigenin antibody–alkaline phos-
phatase conjugate, according to the manufacturer’s instructions
(Boehringer Mannheim).
Immunohistochemical detection of vIL-6 was performed, as de-
scribed elsewhere [5]. Polyclonal rabbit antiserum raised against
vIL-6 peptides was made available by Y. Chang (Columbia Uni-
versity, New York). This vIL-6 antiserum does not cross-react with
human IL-6, as determined by immunohistochemical staining.
Briefly, formalin-fixed, paraffin-embedded cell pellets and tissue
specimens were deparaffinized, incubated in citrate buffer (10 mM,
at pH 6.0) for antigen retrieval, and quenched for 30 min in 0.03%
H202 in PBS. Polyclonal antiserum for vIL-6 was applied at a 1 :
2500 dilution in blocking solution (10% normal goat serum, 1%
bovine serum albumin, and 0.05% Tween-20 in PBS) and incubated
for 18 hr. Immunostaining of vIL-6 was conducted with an avidin-
phosphatase conjugate, followed by Vector Red phosphate chrom-
agens for development (Vector Laboratories, Burlingame, CA). Im-
munohistochemical staining of KS tissue with a monoclonal
antibody (MAb) specific to CD34 (QB-END 10; Seratech, Oxford,
UK) was used to identify KS cells of endothelial origin and to
confirm protein preservation. The CD34 antibody was applied at
a dilution of 1 : 1000 and incubated for 1–2 h. Detection of CD34
was carried out with the diamino-benzidine chromagen (Dako,
Carpinteria, CA).
Sequencing of HHV-8 DNA. Procedures used for library prep-
aration, subcloning, and polymerase chain reaction (PCR) sequenc-
ing have been described elsewhere [8]. Determination of subtype
designation for these samples was based on the analysis of direct
first-round PCR products of the VR-2 subdomain of ORF K1,
using primers LGH 2507 (nt 589–606) and LGH 2508 (nt 840–864).
The sequences of these primers are 5′-CGTCTCGCCTGTCAA-
ATC-3′ and 5′-AGATACCACACATGGTT-3′, respectively.
Results
In situ hybridization and immunohistochemistry vIL-6 de-
tection assays were applied to 3 primary effusion lymphoma
specimens from lymphomas that had appeared in HIV-positive
homosexual men. Two of these were “classic” primary effusion
lymphomas of B cell lineage. The third was CD81, suggesting
a T cell lineage. All 3 effusion lymphomas were dually infected
with Epstein-Barr virus (EBV) and HHV-8. Immunohistochem-
istry with polyclonal rabbit vIL-6 antiserum showed cytoplas-
mic staining of vIL-6 in at least 60% of the B-cell lymphoma
cells of the primary effusion lymphomas in each case (figure
1A). In situ hybridization of cells pelleted from a malignant
effusion lymphoma with a full-length vIL-6 antisense riboprobe
showed vIL-6 transcript in ∼25%–40% of the cells in the 2
tumors of B-cell lineage (figure 1B). Control human lympho-
blastoid cell lines that did not harbor HHV-8, but did produce
human IL-6, showed no vIL-6 signal by either in situ hybrid-
ization or immunohistochemistry (data not shown).
An enlarged lymph node and massively enlarged spleen from
an HIV-positive homosexual man who experienced weight loss,
nightsweats, and fevers also showed vIL-6 expression by in situ
hybridization and immunohistochemistry. Immunohistochem-
istry of vIL-6 protein showed strong cytoplasmic staining in
lymphocytic cells of an HIV-positive Castleman’s disease–like
lesion, and vIL-6 was found in scattered lymphocytic cells in
the mantle zone of both tissues (figure 1C). The inset shows in
situ hybridization with an antisense digoxigenin–labeled vIL-6
riboprobe.
A total of 13 formalin-fixed, paraffin-embedded KS biopsy
specimens from the Johns Hopkins dermatology archives were
studied (table 1), and vIL-6 immunohistochemistry and in situ
hybridization were detected in only a single case. However,
using a CD34-specific MAb, we were able to verify by im-
munohistochemistry that all the KS samples expressed the en-
dothelial cell marker CD34, confirming that the KS tissue was
well-preserved and intact. The integrity of the mRNA in all KS
specimens was confirmed by in situ hybridization with a b-actin
digoxigenin–labeled riboprobe (data not shown).
Intrigued by a report of lytic infection in KS tissue [9], we
obtained specimens from the AIDS Malignancy Bank that had
been previously identified as showing foci of lytic viral infection,
as evidenced by electron microscopy and T1.1 in situ
hybridization.
Each of these KS lesion specimens showed vIL-6 expression
by immunohistochemistry and in situ hybridization, predom-
inantly in infiltrating lymphocytes (figure 1D) but also in oc-
casional spindle-shaped cells with elongated nuclei, character-
istic of KS cells (figure 1F). In situ hybridization confirmed the
presence of vIL-6 RNA in these specimens (figure 1E). The
heterogeneity observed in vIL-6 expression among KS speci-
mens prompted us to consider the possibility that different
strains of virus might be associated with different tendencies
to viral lytic-cycle expression. Analysis of the hypervariable
VR-2 region (amino acids 199–227) of the ORF K1 gene for
each strain by PCR showed that 4 subtypes of virus were rep-
resented among the KS specimens studied (table 1). The subtype
patterns found show some preferential associations with the
patient’s ethnic and geographic backgrounds, which are con-
sistent with more extensive analyses [8]. However, there is no
Figure 1. Detection of viral interleukin-6 (vIL-6) expression in human herpesvirus 8 (HHV-8)–associated diseases. See Results section for
detailed explanation. Hematoxylin (A, C, D, and F) and eosin (B, inset of C, and E) counterstains were applied. Original magnification 3250
(A, B), 364 (C), 3100 (D, E), and 3160 (F, inset of C).
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Table 1. Summary of host factors, human herpesvirus 8 (HHV-8)
strain, and viral interleukin-6 (vIL-6) expression.
KS
specimena
Age
(years) Sex
Race or
ethnic group
HIV
status
HHV-8
strain
vIL-6
expression
JHD
1 65 M White ND C-3 No
2 39 M African American 1 B No
3 37 M White 1 A-4 No
4 37 M White 1 A-2 No
5 37 F White ND A-1 No
6 60 M White ND C-2 No
7 52 M White 2 A-4 No
8 78 M White ND ND No
9 39 M White ND A-4 No
10 81 F White ND ND No
11 33 M White 1 A-1 No
12 79 M White ND ND No
13 56 M Black African 2 B Yes
AMB
1 34 F Hispanic Mexican 1 B Yes
2 47 M Black Haitian 1 B Yes
3 39 M Hispanic Nicaraguan 1 A-4 Yes
4 34 M White 1 A1 Yes
5 27 M White 1 A4 Yes
6 29 F African American 1 D Yes
7 49 M White 1 ND Yes
NOTE. HIV, human immunodeficiency virus; ND, not determined.
a Johns Hopkins Dermatology archives (JHD) and the AIDS Malignancy
Bank (AMB) were the sources of the Kaposi’s sarcoma (KS) specimens.
clear association between HHV-8 subtypes and levels of vIL-6
expression in KS.
Discussion
Our results establish the applicability of in situ hybridization
for the detection of vIL-6 in clinical specimens. These results
demonstrate vIL-6 expression by immunohistochemistry and
in situ hybridization in a variety of HHV-8–associated diseases.
The high percentage of cells expressing vIL-6 in the primary
effusion lymphomas is interesting from several perspectives.
The likelihood that vIL-6, which can substitute for IL-6 as a
B cell growth factor in vitro, contributes to primary effusion
lymphoma pathogenesis and perhaps to maintenance of the
malignant phenotype is high [4, 5]. However, it stands in striking
contrast to the situation with cellular homologues found in
another human tumor–associated gamma herpesvirus, EBV.
The EBV proteins vIL-10 (BCRF1) and vBCL2 (BHRF1) might
also be anticipated to play a role in lymphomagenesis [10, 11].
However, these lytic-cycle genes are expressed only in rare tu-
mor cells or at very low levels in EBV-associated lymphoid
malignancies. Although a background of lytic infection is well
described in EBV malignancies, this is never the predominant
form of infection in tumors, even in HIV-infected patients. The
HHV-8 vIL-6 gene is also a lytic-cycle gene insofar as it is
induced by phorbol esters and butyrate [12]. Its expression in
a large percentage of primary effusion lymphoma cells suggests
either ongoing lytic infection in many of these cells or a more
complex regulation of its expression. We note, however, that
when we culture one of the primary effusion lymphomas, the
percentage of cells expressing vIL-6 decreases over time. In
general, we have found the percentage of positively staining
cells to be between 0.5% and 10% for a number of primary
effusion lymphoma-derived cell lines, including BC-1, BC-2,
BCBL-1, BCP-1, and JSC-1 (present authors, unpublished
data).
Detection of vIL-6 expression in a Castleman’s disease–like
lesion from an HIV-infected patient raises many questions.
HHV-8 infection and vIL-6 expression have previously been
demonstrated in Castleman’s disease tissues in other studies [6,
13]. There has been some uncertainty in the literature with
regard to the appropriateness of a diagnosis of Castleman’s
disease in the setting of HIV infection, because of concerns that
HIV infection itself might lead to similar changes. The dem-
onstration of vIL-6 production in an HIV patient with all of
the clinical features of Castleman’s disease reinforces the sug-
gestion that this may be a distinct entity and raises the possi-
bility that detection of vIL-6 might be a useful tool to distin-
guish between other lymph node pathologies with a similar
appearance and Castleman’s disease.
In regard to KS, our results confirm those of Chang et al.,
that vIL-6 is generally not expressed at detectable levels in KS
specimens [5]. The absence of vIL-6 expression is in contrast
to v-cyclin D and kaposin, which are readily detected in spindle
cells in KS tissues [14, 15]. However, detection by both in situ
hybridization and immunohistochemistry in a subset of spec-
imens highlights the possibility that vIL-6 expression may be
important for KS pathogenesis in some settings. We note that
the cases from the AIDS Malignancy Bank were deliberately
selected because earlier studies of these same specimens showed
foci of lytic infection [9]. To ensure that this selection, rather
than technical differences between the Johns Hopkins speci-
mens and the AIDS Malignancy Bank specimens, accounted
for differences in vIL-6 expression, we studied 10 unselected
specimens from the AIDS Malignancy Bank. Expression of
vIL-6 was detected in only one of these specimens. This was
similar to the one in 13 KS specimens from Johns Hopkins in
which vIL-6 expression was detected. Thus, in specimens from
both sources, it is clear that vIL-6 expression is the exception
rather than the rule. The determinants of vIL-6 expression in
KS lesions are not clear. Host factor data in table 1 do not
hint at any relationship between vIL-6 expression and HIV
status, age, race, or ethnic origin of patients. Similarly, no clear
correlation exists with viral strain.
In conclusion, we confirm that vIL-6 is expressed in a variety
of HHV-8–associated diseases: in a substantial fraction of tu-
mor cells in primary effusion lymphomas, in cells found in the
mantle zone of a case of Castleman’s disease–like lymphad-
enopathy, and in a subset of KS lesions. It is in the KS lesions
that our results differ from those of previous investigators. De-
tection of vIL-6 in these lesions confirms previous evidence of
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lytic-cycle gene expression in these specimens [9]. The role, if
any, of vIL-6 in KS pathogenesis remains to be determined.
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